Rate and risk factors of recurrent immune checkpoint inhibitor-related pneumonitis in patients with lung cancer

BACKGROUND: Immune checkpoint inhibitors (ICIs) have become standard treatments for lung cancer patients. Immune checkpoint inhibitor-related pneumonitis (CIP) was the leading cause of death among ICIs-related adverse events (irAEs). Recurrent episodes of CIP without rechallenge of ICIs were reporte...

Descripción completa

Detalles Bibliográficos
Autores principales: Tao, Haitao, Li, Fangfang, Wu, Dongxiao, Ji, Shiyu, Liu, Qingyan, Wang, Lijie, Liu, Bo, Facchinetti, Francesco, Leong, Tracy L., Passiglia, Francesco, Hu, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988083/
https://www.ncbi.nlm.nih.gov/pubmed/35399572
http://dx.doi.org/10.21037/tlcr-22-168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988083/
https://www.ncbi.nlm.nih.gov/pubmed/35399572
http://dx.doi.org/10.21037/tlcr-22-168

Ejemplares similares